Search

Your search keyword '"Vuillez, Jean-Philippe"' showing total 189 results
Start Over Author "Vuillez, Jean-Philippe"
189 results on '"Vuillez, Jean-Philippe"'

1. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma

Author

Lamy, Thierry, Damaj, Gandhi, Soubeyran, Pierre, Gyan, Emmanuel, Cartron, Guillaume, Bouabdallah, Krimo, Gressin, Rémy, Cornillon, Jérôme, Banos, Anne, Le Du, Katell, Benchalal, Mohamed, Moles, Marie-Pierre, Le Gouill, Steven, Fleury, Joel, Godmer, Pascal, Maisonneuve, Hervé, Deconinck, Eric, Houot, Roch, Laribi, Kamel, Marolleau, Jean Pierre, Tournilhac, Olivier, Branger, Bernard, Devillers, Anne, Vuillez, Jean Philippe, Fest, Thierry, Colombat, Philippe, Costes, Valérie, Szablewski, Vanessa, Béné, Marie C., Delwail, Vincent, and on behalf of the LYSA Group

Published
2018
Full Text
View/download PDF

2. Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

Author

Kraeber-Bodere, Françoise, Pallardy, Amandine, Maisonneuve, Hervé, Campion, Loïc, Moreau, Anne, Soubeyran, Isabelle, Le Gouill, Steven, Tournilhac, Olivier, Daguindau, Etienne, Jardel, Henry, Morineau, Nadine, Bouabdallah, Krimo, Gyan, Emmanuel, Moles, Marie-Pierre, Gressin, Remy, Berthou, Christian, Sadot, Sophie, Moreau, Philippe, Deau, Bénédicte, Bodet-Milin, Caroline, Cazeau, Anne-Laure, Garin, Etienne, Salaun, Pierre-Yves, Vuillez, Jean-Philippe, Gouilleux-Gruart, Valérie, Barbet, Jacques, Wegener, William A, Goldenberg, David M, Lamy, Thierry, and Soubeyran, Pierre

Published
2017
Full Text
View/download PDF

3. Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

Author

de Leiris, Nicolas, Leenhardt, Julien, Boussat, Bastien, Montemagno, Christopher, Seiller, Alexandre, Phan Sy, Olivier, Roux, Julie, Laramas, Mathieu, Verry, Camille, Iriart, Carole, Fiard, Gaelle, Long, Jean-Alexandre, Descotes, Jean-Luc, Vuillez, Jean-Philippe, Riou, Laurent, and Djaileb, Loïc

Published
2020
Full Text
View/download PDF

5. Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years

Author

Olesinski, Jonathan, Mithieux, François, Guillaud, Olivier, Hilleret, Marie-Noëlle, Lombard-Bohas, Catherine, Henry, Luc, Boillot, Olivier, Walter, Thomas, Partensky, Christian, Paliard, Pierre, Valette, Pierre-Jean, Vuillez, Jean-Philippe, Borson-Chazot, Françoise, Scoazec, Jean-Yves, and Dumortier, Jérôme

Published
2017
Full Text
View/download PDF

11. 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma

Author

Salaun, Pierre-Yves, Campion, Loïc, Ansquer, Catherine, Frampas, Eric, Mathieu, Cédric, Robin, Philippe, Bournaud, Claire, Vuillez, Jean-Philippe, Taieb, David, Rousseau, Caroline, Drui, Delphine, Mirallié, Eric, Borson-Chazot, Françoise, Goldenberg, David M., Chatal, Jean-François, Barbet, Jacques, and Kraeber-Bodéré, Françoise

Published
2014
Full Text
View/download PDF

21. Development and Validation of Analytical Methods for Radiochemical Purity of 177 Lu-PSMA-1.

Author

Orhon, Pauline, Desruet, Marie-Dominique, Piquemal, Marie, De Leiris, Nicolas, Djaileb, Loïc, Vuillez, Jean-Philippe, Bedouch, Pierrick, and Leenhardt, Julien

Subjects
RADIOCHEMICAL purification, HIGH performance liquid chromatography, CASTRATION-resistant prostate cancer, ANDROGEN receptors, NUCLEAR medicine, HORMONE therapy
Abstract

Prostate Specific Membrane Antigen (PSMA) is a highly relevant target in nuclear medicine due to its overexpression in prostate cancer. The 68Ga/177Lu-PSMA-1 combination is a theranostic agent for the detection and treatment of tumors overexpressing the PSMA target. Specifically, 177Lu-PSMA-1 is used in the treatment of castration-resistant prostate cancer that is ineffective or intolerant to the latest generation of chemotherapy and/or hormone therapy. This radiopharmaceutical is manufactured in a radiopharmaceutical synthesizing unit and must pass a quality control where the radiochemical purity (RCP) is assessed prior to release of the batch. RCP evaluation is performed by high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC). Since there is no monograph for 177Lu-PSMA-1 in the European Pharmacopoeia, we validate the analytical methods according to the EANM recommendations adapted from ICH Q2. Specificity, linearity, accuracy, precision, intermediate precision, limit of quantification (LOQ) and robustness were described for HPLC and TLC in this study. The results obtained demonstrated the robustness and reliability of the HPLC and TLC analytical methods for the evaluation of the RCP of 177Lu-PSMA-1. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy

Author

Oudoux, Aurore, Salaun, Pierre-Yves, Bournaud, Claire, Campion, Loïc, Ansquer, Catherine, Rousseau, Caroline, Bardet, Stéphane, Borson-Chazot, Françoise, Vuillez, Jean-Philippe, Murat, Arnaud, Mirallié, Eric, Barbet, Jacques, Goldenberg, David M., Chatal, Jean-François, and Kraeber-Bodéré, Françoise

Published
2007

32. Liste des contributeurs

Author

Abgral, Ronan, Beregi, Jean-Paul, Bilfeld, Marie Faruch, Huglo, Damien, Le Jeune, Florence, Pontana, François, Tacher, Vania, Bartoli, Jean-Michel, Boutet, Claire, Boyer, Louis, Brunotte, François, Grenier, Nicolas, Petit, Philippe, Prigent, Alain, Salaün, Pierre-Yves, Abihanna, Michel, Adamsbaum, Catherine, Allary, Alexandre, Anxionnat, René, Attyé, Arnaud, Aubé, Christophe, Auber-Lenoir, Manon, Balleyguier, Corinne, Bailly, Clément, Bani-Sadr, Alexandre, Banos, Jean-Bruno, de Bazelaire, Cédric, Bazot, Marc, Beis, Jean-Noël, Bellin, Marie-France, Benoudiba, Farida, Berteloot, Laureline, Bierry, Guillaume, Blondiaux, Éléonore, Bodard, Sylvain, Bodet-Milin, Caroline, Bonardel, Gérald, Bonneville, Fabrice, Boussel, Loïc, Bousson, Valérie, Boussouar, Samia, Bracard, Serge, Braun, Marc, Bricault, Yvan, Brisse, Hervé, Brunelle, Serge, Brunereau, Laurent, Caramella, Caroline, Carpentier, Françoise, Cassagnes, Lucie, Cassart, Marie, Cassinoto, Christophe, Chammas, Agathe, Chassagnon, Guillaume, Chateil, Jean-François, Chaumet-Riffaud, Philippe, Clément, Olivier, Clerc, Jérôme, Combelles, Sophie, Cotten, Anne, Cotton, François, Cuny, Emmanuel, Cyteval, Catherine, Dabadie, Alexia, Dang, Lan-Anh, Daraï, Émile, Darcourt, Jacques, Dechoux-Vodovar, Sophie, Delacourt, Christophe, Demondion, Xavier, Devred, Philippe, Dormont, Didier, Douek, Philippe, Dournes, Gaël, Dousset, Vincent, Dubrulle, Frédérique, Ducou-Le-Pointe, Hubert, Durand, Chantal, Durand, Emmanuel, Duron, Loïc, Edjilali-Goujon, Myriam, Elmaleh, Monique, Ernst, Olivier, Felici, Florence, Ferey, Solène, Ferrié, Jean-Claude, Fleury, Vincent, Fournier, Laure, Gach, Pierre, Galanaud, Damien, Garcier, Jean-Marc, Gauvrit, Jean-Yves, Ghasarossian, Christian, Gocko, Xavier, Gonzalez, Sandra, Gorincour, Guillaume, Grand, Sylvie, Grange, Loïc, Grévent, David, Guéret, Pascal, Hamet, Blandine, Hélénon, Olivier, Héran, Françoise, Hoeffel, Christine, Humbert, Olivier, Imbert, Patrick, Jacquier, Alexis, Kas, Aurélie, Kraeber-Bodéré, Francoise, Krainik, Alexandre, Kuchcinski, Grégory, de Labriolle-Vaylet, Claire, Lainé, Xavier, Laissy, Jean-Pierre, Laurent, François, Lecler, Augustin, Leclerc, Xavier, Le Corroller, Thomas, Lederlin, Mathieu, Legallois, Damien, Leger, Thomas, Lemaître, Laurent, Lenoir, Marion, Le Roux, Pierre-Yves, Leruste, Sébastien, Lignères, Marie, Lucidarme, Olivier, Manrique, Alain, de Margerie-Mellon, Constance, Maugars, Yves, Meder, Jean-François, Merzoug, Valérie, Midulla, Marco, Millet, Ingrid, Montaudon, Michel, Morel, Baptiste, Moulin, Thierry, Naggara, Olivier, Oppenheim, Catherine, Palard, Xavier, Perdrix, Corinne, Pescatori, Lorenzo, Planel, Sophie, Poncelet, Édouard, Proisy, Maia, Pruvo, Jean-Pierre, Puech, Philippe, Pyatigorskaya, Nadya, Querellou-Lefranc, Solène, Renard-Penna, Raphaëlle, Robin, Philippe, Rocher, Laurence, Rodriguez, Christine, Ronot, Maxime, Rousseau, Caroline, Rousset, Jean, Rouvière, Olivier, Rouzet, François, Roy, Catherine, Savoye-Collet, Céline, Simon, Clémentine, Souillard-Scemama, Raphaëlle, Soussan, Michael, Soyer, Philippe, Taourel, Patrice, Tasu, Jean-Pierre, Thomassin-Naggara, Isabelle, Vernet-Kovacsik, Hélène, Vidal, Vincent, Vignes, Jean-Rodolphe, Vija, Lavina, Vuillez, Jean-Philippe, and Wagner, Mathilde

Published
2022
Full Text
View/download PDF

36. Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

Author

Kraeber-Bodere, Françoise, primary, Pallardy, Amandine, additional, Maisonneuve, Hervé, additional, Campion, Loïc, additional, Moreau, Anne, additional, Soubeyran, Isabelle, additional, Le Gouill, Steven, additional, Tournilhac, Olivier, additional, Daguindau, Etienne, additional, Jardel, Henry, additional, Morineau, Nadine, additional, Bouabdallah, Krimo, additional, Gyan, Emmanuel, additional, Moles, Marie-Pierre, additional, Gressin, Remy, additional, Berthou, Christian, additional, Sadot, Sophie, additional, Moreau, Philippe, additional, Deau, Bénédicte, additional, Bodet-Milin, Caroline, additional, Cazeau, Anne-Laure, additional, Garin, Etienne, additional, Salaun, Pierre-Yves, additional, Vuillez, Jean-Philippe, additional, Gouilleux-Gruart, Valérie, additional, Barbet, Jacques, additional, Wegener, William A, additional, Goldenberg, David M, additional, Lamy, Thierry, additional, and Soubeyran, Pierre, additional

Published
2017
Full Text
View/download PDF

37. The impacts of blended learning design in first year medical studies

Author

Gillois, Pierre, Bosson, Jean Luc, Genty, Céline, Vuillez, Jean-Philippe, Romanet, Jean-Paul, Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-IMAG-ThEMAS), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), CHU Grenoble, Division de Biostatistiques, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Radiopharmaceutiques biocliniques, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Centre Hospitalier Universitaire de Grenoble

Subjects
[STAT.AP]Statistics [stat]/Applications [stat.AP], Models, Educational, MESH: Curriculum, Teaching, [SCCO.COMP]Cognitive science/Computer science, [SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM], MESH: Models, Educational, MESH: France, [STAT.ML]Statistics [stat]/Machine Learning [stat.ML], MESH: Education, Medical, Undergraduate, [MATH.MATH-ST]Mathematics [math]/Statistics [math.ST], MESH: Educational Measurement, Curriculum, Educational Measurement, France, [STAT.ME]Statistics [stat]/Methodology [stat.ME], MESH: Teaching, Education, Medical, Undergraduate
Abstract

International audience; In the first year of medical studies in France, students prepare for a highly selective entrance exam limited by numerus clausus into the second year. We have discontinued live lectures, made maximum use of new information and communication technologies and introduced tutorials in an attempt to make the first year more equitable and to personalise teaching. The reform is based on blended learning with flipped classroom organized into a four-week cycles of different activities. Each cycle corresponds to a learning module. The teachers' and students' opinions were analysed to evaluate the reforms and allow teaching methods to be adapted accordingly. The student profiles at registration and success in the exams following the reform are described. The tutorial's notes are correlated to the final scores at the entrance exam. The keys to success seem to be modified by the reform providing greater equality of opportunity between students. The factors associated to success are baccalaureate highest grades, high School Specialisation (maths, physics or earth and life sciences) and repeating the first year class. The use of blended learning allows us to face the increase of student enrolment, and to facilitate the acceptance of these pedagogical methods for both students and teachers.

Published
2015

38. Liste des contributeurs

Author

Abgral, Ronan, Bartoli, Jean-Michel, Boutet, Claire, Darcourt, Jacques, Boyer, Louis, Brunotte, François, Grenier, Nicolas, Petit, Philippe, Prigent, Alain, Salaün, Pierre-Yves, Abihanna, Michel, Adamsbaum, Catherine, Allary, Alexandre, Anxionnat, René, Attyé, Arnaud, Aubé, Christophe, Balleyguier, Corinne, Banos, Jean-Bruno, de Bazelaire, Cédric, Bazot, Marc, Beis, Jean-Noël, Benoudiba, Farida, Bérégi, Jean-Paul, Bierry, Guillaume, Blondiaux, Eléonore, Bodet-Milin, Caroline, Bonardel, Gérald, Bonneville, Fabrice, Boussel, Loïc, Bousson, Valerie, Bracard, Serge, Braun, Marc, Bricault, Yvan, Brisse, Hervé, Cassart, Marie, Carpentier, Françoise, Cassinoto, Christophe, Chateil, Jean-François, Chaumet-Riffaud, Philippe, Clément, Olivier, Clerc, Jérôme, Combelles, Sophie, Cotten, Anne, Cotton, François, Cuny, Emmanuel, Cyteval, Catherine, Dabadie, Alexia, Daraï, Émile, Dechoux-Vodovar, Sophie, de Labriolle-Vaylet, Claire, Delacourt, Christophe, Demondion, Xavier, Devred, Philippe, Dormont, Didier, Douek, Philippe, Dubrulle, Frédérique, Dousset, Vincent, Ducou-le-Pointe, Hubert, Durand, Chantal, Durand, Emmanuel, Duron, Loïc, Elmaleh, Monique, Ernst, Olivier, Felici, Florence, Ferey, Solène, Ferrié, Jean-Claude, Fleury, Vincent, Fournier, Laure, Gach, Pierre, Galanaud, Damien, Garcier, Jean-Marc, Gauvrit, Jean-Yves, Ghasarossian, Christian, Gocko, Xavier, Gonzalez, Sandra, Gorincour, Guillaume, Grand, Sylvie, Grange, Loïc, Grévent, David, Guéret, Pascal, Hélénon, Olivier, Héran, Françoise, Imbert, Patrick, Jacquier, Alexis, Kas, Aurélie, Kraeber-Bodéré, Francoise, Krainik, Alexandre, Kuchcinski, Grégory, Lainé, Xavier, Laissy, Jean-Pierre, Laurent, François, Leclerc, Xavier, Le Corroller, Thomas, Lederlin, Mathieu, Lemaître, Laurent, Legallois, Damien, Lenoir, Marion, Le Roux, Pierre-Yves, Leruste, Sébastien, Lignères, Marie, Lucidarme, Olivier, Manrique, Alain, Maugars, Yves, Meder, Jean-François, Merzoug, Valérie, Millet, Ingrid, Montaudon, Michel, Morel, Baptiste, Moulin, Thierry, Naggara, Olivier, Oppenheim, Catherine, Palard, Xavier, Perdrix, Corinne, Planel, Sophie, Poncelet, Édouard, Proisy, Maia, Pruvo, Jean-Pierre, Querellou-Lefranc, Solène, Renard-Penna, Raphaëlle, Robin, Philippe, Rodriguez, Christine, Ronot, Maxime, Rousseau, Caroline, Rousset, Jean, Rouvière, Olivier, Rouzet, François, Roy, Catherine, Simon, Clémentine, Souillard-Scemama, Raphaëlle, Soussan, Michael, Soyer, Philippe, Tacher, Vania, Taourel, Patrice, Tasu, Jean-Pierre, Thomassin-Naggara, Isabelle, Vernet-Kovacsik, Hélène, Vidal, Vincent, Vignes, Jean-Rodolphe, Vija, Lavina, and Vuillez, Jean-Philippe

Published
2019
Full Text
View/download PDF

39. ¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma

Author

Salaun, Pierre-Yves, Campion, Loïc, Ansquer, Catherine, Frampas, Eric, Mathieu, Cédric, Robin, Philippe, Bournaud, Claire, Vuillez, Jean-Philippe, Taieb, David, Rousseau, Caroline, Drui, Delphine, Mirallié, Eric, Borson-Chazot, Françoise, Goldenberg, David M, Chatal, Jean-François, Barbet, Jacques, Kraeber-Bodéré, Françoise, Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Centre René Gauducheau, CRLCC René Gauducheau, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Service de Médecine Nucléaire [Nantes], Hôpital Laennec, Département de radiologie, Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Médecine Nucléaire, CHU de Lyon, CHU de Lyon-CHU de Lyon, Radiopharmaceutiques biocliniques, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Département d'endocrinologie, Clinique de chirurgie digestive et endocrinienne, IMAD, Eq 4, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Lyon-Est (GHE), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Centre de médecine nucléaire, Fédération d'endocrinologie-Groupement hospitalier Lyon-Est-Fédération d'endocrinologie-Groupement hospitalier Lyon-Est, Immunomedics, ARRONAX, and Université de Nantes (UN)

Subjects
Adult, Male, Calcitonin, Survival, [SDV]Life Sciences [q-bio], Doubling time, Multimodal Imaging, CEA, Fluorodeoxyglucose F18, Predictive Value of Tests, Medullary thyroid carcinoma, Humans, Thyroid Neoplasms, Aged, Aged, 80 and over, Middle Aged, Radioimmunotherapy, Carcinoma, Neuroendocrine, Treatment Outcome, Carcinoma, Medullary, Positron-Emission Tomography, FDG PET, Female, Radiopharmaceuticals, Surrogate marker, Tomography, X-Ray Computed, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; PET is a powerful tool for assessing targeted therapy. Since (18)F-FDG shows a potential prognostic value in medullary thyroid carcinoma (MTC), this study evaluated (18)F-FDG PET alone and combined with morphological and biomarker evaluations as a surrogate marker of overall survival (OS) in patients with progressive metastatic MTC treated with pretargeted anti-CEA radioimmunotherapy (pRAIT) in a phase II clinical trial. Patients underwent PET associated with morphological imaging (CT and MRI) and biomarker evaluations, before and 3 and 6 months, and then every 6 months, after pRAIT for 36 months. A combined evaluation was performed using anatomic, metabolic and biomarker methods. The prognostic value of the PET response was compared with demographic parameters at inclusion including age, sex, RET mutation, time from initial diagnosis, calcitonin and CEA concentrations and doubling times (DT), SUVmax, location of disease and bone marrow involvement, and with response using RECIST, biomarker concentration variation, impact on DT, and combined methods. Enrolled in the study were 25 men and 17 women with disease progression. The median OS from pRAIT was 3.7 years (0.2 to 6.5 years) and from MTC diagnosis 10.9 years (1.7 to 31.5 years). After pRAIT, PET/CT showed 1 patient with a complete response, 4 with a partial response and 24 with disease stabilization. The combined evaluation showed 20 responses. For OS from pRAIT, univariate analysis showed the prognostic value of biomarker DT (P = 0.011) and SUVmax (P = 0.038) calculated before pRAIT and impact on DT (P = 0.034), RECIST (P = 0.009), PET (P = 0.009), and combined response (P = 0.004) measured after pRAIT. PET had the highest predictive value with the lowest Akaike information criterion (AIC 74.26) as compared to RECIST (AIC 78.06), biomarker variation (AIC 81.94) and impact on DT (AIC 79.22). No benefit was obtained by combining the methods (AIC 78.75). This result was confirmed by the analysis of OS from MTC diagnosis. (18)F-FDG PET appeared as the most potent and simplest prognostic method to predict survival in patients with progressive MTC treated with pRAIT. Biomarker DT before pRAIT also appeared as an independent prognostic factor, but no benefit was found by adding morphological and biomarker evaluation to PET assessment.

Published
2014

41. PET Adapted Salvage Therapy for Advanced Hodgkin Lymphomas: Towards the Suppression of Positive Interim PET Unfavorable Prognosis? a Report of the Goelams Multicentric Phase 2 Trial LH2007

Author

Carras, Sylvain, primary, Dubois, Benjamin, additional, Senecal, Delphine, additional, Quittet, Philippe, additional, Vuillez, jean-Philippe, additional, peoc'H, Michel, additional, Jais, jean-Philippe, additional, Lamy, Thierry, additional, and Molina, Lysiane, additional

Published
2015
Full Text
View/download PDF

42. Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France

Author

Le Roux, Pierre-Yves, primary, Pelletier-Galarneau, Matthieu, additional, De Laroche, Romain, additional, Hofman, Michael S., additional, Zuckier, Lionel S., additional, Roach, Paul, additional, Vuillez, Jean-Philippe, additional, Hicks, Rodney J., additional, Le Gal, Grégoire, additional, and Salaun, Pierre-Yves, additional

Published
2015
Full Text
View/download PDF

43. Innovative radioisotopes for preclinical and clinical studies in nuclear medicine

Author

Assmann Walter, LMU Munich, Barbet Jacques, Arronax Nantes, Chatal Francois, Arronax Nantes, Fagret Daniel, CHU Grenoble, Haddad Ferid, Subatech Nantes, Hohn Alexander, PSI, Jensen Mikael, DTU Risø, Köster Ulli, ILL Grenoble, Miederer Matthias, Universitätsklinik Mainz, Pichler Bernd, Universitätklinik Tübingen, Polack Benoit, CHU Grenoble, Ratib Osman, HUG Geneve, Schibli Roger, PSI, Seimbille Yann, HUG Geneve, Tamburella Claire, HUG Geneve, Türler Andreas, PSI, Vuillez Jean-Philippe, CHU Grenoble, Wiehr Stefan, Universitätklinik Tübingen, and Zhernosekov Konstantin, PSI

Subjects
Detectors and Experimental Techniques
Published
2010

44. Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD+C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell Lymphoma Patients (MCL): Prognostic Value of FDG-PET/CT

Author

Dubreuil, Julien, primary, Houot, Roch, additional, Le Gouill, Steven, additional, Mounier, Christiane, additional, Courby, Stéphane, additional, Dartigeas, Caroline, additional, Bouabdallah, Krimo, additional, Moles, Marie Pierre, additional, Magda, Alexis, additional, Tournilhac, Olivier, additional, Ojeda Uribe, Mario, additional, Bourre, Jean Cyril, additional, Bodet-Milin, Caroline, additional, Vuillez, Jean-Philippe, additional, and Gressin, Remy, additional

Published
2014
Full Text
View/download PDF

45. [Imaging and PET/CT of lung cancer]

Author

Ferretti, Gilbert, Jankowski, Adrien, Calizzano, Alex, Moro-Sibilot, Denis, Vuillez, Jean Philippe, Pôle d'imagerie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique de pneumologie, CHU Grenoble, and Vesin, Aurélien

Subjects
Male, MESH: Aged, Lung Neoplasms, MESH: Humans, MESH: Male, MESH: Positron-Emission Tomography, MESH: Lung Neoplasms, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Positron-Emission Tomography, Humans, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Tomography, X-Ray Computed, MESH: Tomography, X-Ray Computed, Aged
Abstract

International audience; Lung cancer is one of the most frequently occurring cancer in the world. Imaging plays a critical role for screening, diagnosing, staging, and following patients. Although morphologic imaging such as chest X-ray and CT are still useful for these purpose, major limitations occur in the proper evaluation of diagnosing and staging. Metabolic imaging using PET significantly increases the accuracy of staging. This paper will review the role of imaging in patients suspected or diagnosed with lung cancer.

Published
2008

46. Sentinel lymph node biopsy in cutaneous melanoma: outcome after 5-years follow-up

Author

Cuchet, Elsa, Pinel, Nicole, Corcella, Denis, Vuillez, Jean-Philippe, Lebeau, Jacques, Moutet, François, Colonna, Marc, Leccia, Marie-Thérèse, Département Pluridisciplinaire de Médecine, Dermatologie, CHU Grenoble-Hôpital Michallon, Département d'anatomie et cythologie pathologique, Service de chirurgie plastique et maxillofaciale, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service de médecine nucléaire et biophysique, Département de cancérologie et d'hématologie, and Vesin, Aurélien

Subjects
Adult, Male, Skin Neoplasms, MESH: Melanoma, MESH: Sentinel Lymph Node Biopsy, MESH: Lymphatic Metastasis, Kaplan-Meier Estimate, Disease-Free Survival, MESH: Prognosis, MESH: Aged, 80 and over, Humans, MESH: Kaplan-Meiers Estimate, Melanoma, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH: Humans, Sentinel Lymph Node Biopsy, MESH: Skin Neoplasms, MESH: Retrospective Studies, MESH: Adult, MESH: Neoplasm Staging, MESH: Follow-Up Studies, Middle Aged, Prognosis, MESH: Male, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Lymphatic Metastasis, MESH: Disease-Free Survival, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Female, Follow-Up Studies
Abstract

International audience; Sentinel lymph node procedure for cutaneous melanoma is largely used and sentinel lymph node status is an important prognostic factor. Few French centers have reported their experience and data. We analysed technique feasibility, recurrence-free and overall-survival rates at 36 and 60 months for the first 62 patients submitted to this technique. The positivity of sentinel lymph nodes was 17.7%. Recurrence-free survival at 36 and 60 months was of 85% and 78% respectively for patients with negative sentinel lymph nodes, whereas the rates were of 45% and 36% respectively for patients with positive sentinel lymph nodes (p = 0.0046). The overall survival rate was of 94% at 36 months and 85% at 60 months for negative patients as opposed to 82% at 36 months and 47% at 60 months for positive patients (p = 0.0019). In our experience, sentinel lymph node technique is a safe procedure with few complications and good pronostic value. This technique allows the identification of patients with a high risk of recurrence who could benefit from early adjuvant therapeutic management. However, these results show that the survival rate of patients with positive sentinel lymph nodes remains significantly lower, even when elective lymph node dissection is performed.

Published
2007
Full Text
View/download PDF

47. Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years.

Author

Olesinski, Jonathan, Mithieux, François, Guillaud, Olivier, Hilleret, Marie-Noëlle, Lombard-Bohas, Catherine, Henry, Luc, Boillot, Olivier, Walter, Thomas, Partensky, Christian, Paliard, Pierre, Valette, Pierre-Jean, Vuillez, Jean-Philippe, Borson-Chazot, Françoise, Scoazec, Jean-Yves, Dumortier, Jérôme, Mithieux, François, Hilleret, Marie-Noëlle, Borson-Chazot, Françoise, and Dumortier, Jérôme

Subjects
IODINE radioisotopes, HEPATOCELLULAR carcinoma, LIVER tumors, LONGITUDINAL method, PROGNOSIS, RADIOTHERAPY, SAFETY, DISEASE relapse, VEGETABLE oils, TREATMENT effectiveness, RETROSPECTIVE studies, DIAGNOSIS, THERAPEUTICS
Abstract

Objective: Hepatocellular carcinoma (HCC) has high recurrence rate after curative treatment. The aim of the present study was to report our experience with adjuvant use of 131I-lipiodol after curative treatment of HCC in terms of recurrence and survival in a large cohort of patients with a long follow-up.Methods: All patients treated with 131I-lipiodol after curative treatment of HCC in two French centers from 1991 to 2009 were included in a retrospective cohort study.Results: One hundred and six patients were included. The median (range) follow-up was 6 years (0.3-22). Forty-three patients (41%) had cirrhosis. Recurrence-free survival rates at 1, 2, 5, 10, and 20 years were 73, 57, 40, 30, and 14%, respectively. Cirrhosis was an independent predictive factor of recurrence [RR = 1.18, 95% CI (1.11-3.02), p = 0.019]. Overall, survival rates at 1, 2, 5, 10, and 20 years were 90, 83, 59, 37, and 23%, respectively. Prognostic factors were recurrence [RR = 2.73, 95% CI (1.35-5.54); p = 0.005], age over 60 years (RR = 1.91, 95% CI [1.02-3.61]; p = 0.044), and tumor number over 3 [RR = 3.31, 95% CI (1.25-8.77); p = 0.016].Conclusion: Our results suggest that the effect of 131I-lipiodol after curative treatment of HCC could be related to a beneficial impact on risk factors of early tumor recurrence. This could be evaluated in further studies using modern radioembolization methods. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

48. Adjuvant Intraarterial Lipiodol or 131I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial

Author

Dumortier, Jérôme, primary, Decullier, Evelyne, additional, Hilleret, Marie-Noëlle, additional, Bin-Dorel, Sylvie, additional, Valette, Pierre-Jean, additional, Boillot, Olivier, additional, Partensky, Christian, additional, Letoublon, Christian, additional, Ducerf, Christian, additional, Leroy, Vincent, additional, Vuillez, Jean-Philippe, additional, and Borson-Chazot, Françoise, additional

Published
2014
Full Text
View/download PDF

50. Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial

Author

Kraeber-Bodere, Françoise, primary, Pallardy, Amandine, additional, Le Gouill, Steven, additional, Maisonneuve, Hervé, additional, Lamy, Thierry, additional, Bouabdallah, Krimo, additional, Milpied, Noel, additional, Jardel, Henry, additional, Deconinck, Eric, additional, Morineau, Nadine, additional, Foussard, Charles, additional, Brion, Annie, additional, Gressin, Remy, additional, Tournilhac, Olivier, additional, Gyan, Emmanuel, additional, Moreau, Anne, additional, Berthou, Christian, additional, Dreyfus, Francois, additional, Bodet-Milin, Caroline, additional, Cazeau, Anne-Laure, additional, Garin, Etienne, additional, Vuillez, Jean-Philippe, additional, Campion, Loic, additional, Moreau, Philippe, additional, Wegener, William A, additional, Goldenberg, David M, additional, and Soubeyran, Pierre, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results